Our ProductsAGGRASTAT® - US GP IIb/IIIa inhibitor market - $400 million (AGGRASTAT® + two competitors)TARDOXALTM - in Phase II clinical development for the treatment of Tardive Dys...more...See more text
Company HistoryOur business began in the late 1980's with lab scale R&D using fermentation based pharmaceutical products. Read More...Facility OverviewOur 87,000 square foot facili...more...See more text
ContactEnhanced Accelerator ModelFounded in 1997 by renowned bio-entrepreneur Dr. Albert D. Friesen, the GVI team has extensive experience in technology development to offer its cl...more...See more text
Healthmark Ltd. is your one-stop destination for pharmaceutical products and medical services in Ville Saint-Laurent. We provide medication safety systems, packaging and other serv...more...See more text
Categories: Public Communication|YervoyMISSISSAUG,a ON and MONTREAL, QC, September 4, 2013Onglyza® (saxagliptin) Achieves Primary Safety Endpoint, Demonstrating No Increased Risk f...more...See more text